The uneven heart monitoring results of fitness trackers

Wearable devices that can track heart rates aren’t too far off in their results, but their accuracy goes down when people would need them the most.

"We have patients come in who have different kinds of monitors like these. Many of them are very concerned because they've recorded values that seem way outside of the normal range," Marc Gillinov, MD, a cardiac surgeon at the Cleveland Clinic told NPR.

Gillinov was the lead author of a study published in JAMA Cardiology which found wrist-worn fitness trackers became less accurate with more vigorous exercise. They weren’t off by muchApple Watch and Mio Alpha wristbands had about 91 percent accuracy, while FitBit Charge HR and Basis Peak were around 80 percent—but for cardiac patients or athletes who are closely monitoring their heart rates, that’s not good enough.

“For those groups, I'd recommend medical-quality chest-strap monitors," Gillinov said, though he added the devices aren’t dangerous, in his opinion, just not all that useful.

For more on why these wearable devices encounter the same accuracy problems as hospital equipment, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.